EUVIMEDEUVIMED entdecken
Crossref

Analysis of bioactive components and synergistic action mechanism of ShuGan-QieZhi Capsule for treating non-alcoholic fatty liver disease

Tong Zhu, Xiaohui Huang, Hongyan Zhu, Jihui Chen, Huijuan Yao, Yufeng Zhang, Haibing Hua, Jian Zhang, Jia Qi

Phytomedicine · 2024

DOI: 10.1016/j.phymed.2023.155173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2024. Verfasst von Tong Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Rd.,Yangpu District,…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Shanghai Science and Technology Development Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: ShuGan-QieZhi capsule (SGQZC) is a traditional Chinese preparation used to treat hyperlipidemia and obesity, even non-alcoholic fatty liver disease (NAFLD). However, its therapeutic effects, main bioactive ingredients, as well as potential mechanisms for NAFLD are still unclear. PURPOSE: To investigate the pharmacological effect, main active ingredients, and mechanisms of SGQZC against high-fat diet (HFD)-induced NAFLD in mice. METHODS: NAFLD models were established by feeding C57BL/6 J mice an HFD for 24 weeks. From the 12th week, HFD-fed mice received daily gavage of either SGQZC or silibinin for 12 weeks. Hepatic hypertrophy parameters, along with hepatic and systemic lipid metabolism changes in NAFLD mice, were assessed. Oil red O and histopathological staining techniques determined lipid accumulation and liver injury severity. qRT-PCR analysis measured the expression of genes tied to liver lipid metabolism and inflammation. HPLC-MS/MS identified the primary components of SGQZC in the serum. Human normal hepatocytes (LO2) and hepatic stellate cells (LX-2) were used to screen SGQZC's bioactive ingredients. Network pharmacological analysis, transcriptomics, and western blotting delved into SGQZC's synergistic mechanisms against NAFLD. RESULTS: SGQZC ameliorated abnormal lipid metabolism and liver hypertrophy in mice with HFD-induced NAFLD, consequently reducing hepatic lipid accumulation, inflammatory cell infiltration, and liver impairment. Eight crucial components of SGQZC were detected in serum using HPLC-MS/MS and were found to effectively attenuate lipid accumulation and inflammation in liver cells. Further investigation indicated that SGQZC modulates MAPK pathway and AKT/NF-κB pathway, subsequently improving lipid metabolism and inflammation. CONCLUSION: SGQZC alleviates NAFLD by synergistically modulating the MAPK-mediated lipid metabolism and inhibiting AKT/NF-κB pathways-mediated inflammation. Our findings reveal the enormous potential of SGQZC for the treatment of NAFLD, providing a possible new clinical therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHumansMiceAnimalsNF-kappa BProto-Oncogene Proteins c-aktTandem Mass SpectrometryMice, Inbred C57BLLiverInflammationLipid MetabolismDiet, High-FatLipidsHypertrophy

Stichwörter der Autor:innen

Lipid metabolismNon-alcoholic fatty liver diseaseShuGan-QieZhi capsuleinflammation

Substanzen

NF-kappa BProto-Oncogene Proteins c-aktLipids

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Rd.,Yangpu District, Shanghai, 200092, China.
  • Department of Pulmonary and Critical Care Medicine, Jiangyin Hospital of Traditional Chinese Medicine, Jiangyin Hospital Affiliated to Nanjing University of Chinese Medicine, Jiangyin, Jiangsu, 214400, China.
  • Department of Gastroenterology, Jiangyin Hospital of Traditional Chinese Medicine, Jiangyin Hospital Affiliated to Nanjing University of Chinese Medicine, Jiangyin, Jiangsu, 214400, China.
  • Department of Clinical Pharmacy, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Rd.,Yangpu District, Shanghai, 200092, China. Electronic address: zhangjian@xinhuamed.com.…
  • Department of Clinical Pharmacy, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Rd.,Yangpu District, Shanghai, 200092, China. Electronic address: qijia@xinhuamed.com.cn.

Förderung

  • Shanghai Science and Technology Development Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Zhu, T., Huang, X., Zhu, H., Chen, J., Yao, H., Zhang, Y., Hua, H., Zhang, J., & Qi, J. (2024). Analysis of bioactive components and synergistic action mechanism of ShuGan-QieZhi Capsule for treating non-alcoholic fatty liver disease. Phytomedicine. https://doi.org/10.1016/j.phymed.2023.155173

Vancouver

Zhu T, Huang X, Zhu H, Chen J, Yao H, Zhang Y, et al. Analysis of bioactive components and synergistic action mechanism of ShuGan-QieZhi Capsule for treating non-alcoholic fatty liver disease. Phytomedicine. 2024. doi:10.1016/j.phymed.2023.155173

BibTeX
@article{Zhu2024,
  author = {Zhu, Tong and Huang, Xiaohui and Zhu, Hongyan and Chen, Jihui and Yao, Huijuan and Zhang, Yufeng and Hua, Haibing and Zhang, Jian and Qi, Jia},
  title = {Analysis of bioactive components and synergistic action mechanism of ShuGan-QieZhi Capsule for treating non-alcoholic fatty liver disease},
  journal = {Phytomedicine},
  year = {2024},
  doi = {10.1016/j.phymed.2023.155173}
}
Kostenlos starten →